Human in vitro models for understanding mechanisms of autism spectrum disorder.
Aaron Gordon, Daniel H Geschwind
PMID 32299488WHAT IT FOUND
Stem cell models reveal early brain development changes in autism, but findings are inconsistent and based on tiny samples.
These models cannot explain behavior or guide clinical therapy, serving only as laboratory tools for future mechanistic research.
Key findings
01Studies using stem cells from individuals with autism often show conflicting results regarding cell proliferation and neuronal differentiation, likely due to small sample sizes and varying culturing methods.
02Genetically defined forms of autism show more coherent cellular changes in stem cell models than idiopathic cases, with many forms exhibiting decreased neuronal activity and altered synaptic structure.
03A major limitation of these models is the inability to assess behavior, meaning cellular findings cannot be directly translated to patient symptoms or therapeutic outcomes.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The models cannot assess behavior, so cellular findings do not translate to functional or communicative outcomes relevant to therapy. Sample sizes in the reviewed studies are very small (often 1-8 individuals), leading to low statistical power and inconsistent replication. Culturing methods vary widely between studies, making it difficult to compare results or determine if findings are biological artifacts. The review focuses on early developmental mechanisms in a dish, which may not reflect the complex, ongoing neural changes in living patients.
Declared interests
Funding was provided by the Autism Science Foundation, Brain and Behavior Foundation, National Institute of Mental Health, and California Institute of Regenerative Medicine.
The easy way to misread this
Do not interpret cellular changes in stem cells as evidence of current brain pathology or a target for treatment in living patients. These are laboratory models of early development, not clinical tools, and they cannot predict how a patient will respond to therapy.